To include your compound in the COVID-19 Resource Center, submit it here.

Fixing FDA’s FAERS

FAERS is an underexploited but undercurated resource for de-risking tox

Last week FDA announced a new searchable format for its adverse events reporting database, making it easier for drug developers to use the tool to de-risk drug candidates. But according to an August publication from Novartis AG and UCSF, the database needs some scrubbing before it can live up to its promise.

The FDA Adverse Event Reporting System (FAERS) was created to collect information on adverse events that arise outside of the carefully controlled settings of clinical trials after a drug has made it onto the market, including low frequency AEs and those caused by combinations of therapies not tested in the clinic.

FAERS data became publicly available in 2013 and the database is emerging as a key resource for post-marketing pharmacovigilance. It contains roughly nine million AE reports across a vast array of licensed drugs, with about a million new reports added annually.

But the database also represents a potential treasure trove for drug developers aiming to look for clues to human toxicities their preclinical drug candidates might produce.

Using FAERS, any company can compare the chemical structure and targets of its drug candidates to those of marketed therapies, offering a powerful predictive tool to complement standard in vitro and animal toxicology studies. Tapping the data should help companies select the safest targets and compounds, and begin developing risk mitigation strategies early in the drug development process before a

Read the full 2284 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE